[{"id":"c4e11a53-59fb-4852-8365-a515e03c2836","acronym":"","url":"https://clinicaltrials.gov/study/NCT05524844","created_at":"2022-09-01T12:58:59.184Z","updated_at":"2024-07-02T16:34:59.281Z","phase":"","brief_title":"The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)","source_id_and_acronym":"NCT05524844","lead_sponsor":"Columbia University","biomarkers":" NOTCH3","pipe":" | ","alterations":" NOTCH3 expression","tags":["NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH3 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 02/09/2021","start_date":" 02/09/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-04"},{"id":"a57663a3-200f-4a64-8df5-537b7c4835d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04780568","created_at":"2023-12-11T17:16:35.473Z","updated_at":"2024-07-02T16:35:26.635Z","phase":"Phase 1","brief_title":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04780568","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" EGFR • NOTCH3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR • NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-11"},{"id":"6624a35f-cee8-4450-8d7f-b7b9c40ad3a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01647828","created_at":"2023-02-16T00:00:29.876Z","updated_at":"2024-07-02T16:35:55.487Z","phase":"Phase 1b/2","brief_title":"A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer","source_id_and_acronym":"NCT01647828","lead_sponsor":"OncoMed Pharmaceuticals, Inc.","biomarkers":" NOTCH3","pipe":" | ","alterations":" NOTCH3 expression • NOTCH3 overexpression","tags":["NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH3 expression • NOTCH3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • tarextumab (OMP-59R5)"],"overall_status":"Completed","enrollment":" Enrollment 217","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2023-02-15"}]